Apellis Pharmaceuticals Inc [APLS] stock prices are down -1.13% to $20.1 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APLS shares have gain 5.79% over the last week, with a monthly amount drifted -18.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo started tracking the stock with Overweight rating on October 15, 2025, and set its price target to $32. On September 26, 2025, downgrade downgraded it’s rating to Sell but maintained its price target of $18 on the stock. Raymond James downgraded its rating to an Outperform but stick to its price target of $52 on May 09, 2025. BofA Securities downgraded its rating to a Neutral but $23 remained the price target by the analyst firm on May 09, 2025. Cantor Fitzgerald started tracking with an Overweight rating for this stock on April 29, 2025, and assigned it a price target of $44. In a note dated December 17, 2024, Goldman downgraded a Neutral rating on this stock but restated the target price of $36.
The stock price of Apellis Pharmaceuticals Inc [APLS] has been fluctuating between $16.10 and $35.72 over the past year. Currently, Wall Street analysts expect the stock to reach $31.33 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $20.1 at the most recent close of the market. An investor can expect a potential return of 55.87% based on the average APLS price forecast.
Analyzing the APLS fundamentals
The Apellis Pharmaceuticals Inc [NASDAQ:APLS] reported sales of 1.02B for trailing twelve months, representing a surge of 132.98%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.86 points at the first support level, and at 19.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.45, and for the 2nd resistance point, it is at 20.81.
Ratios To Look Out For
It’s worth pointing out that Apellis Pharmaceuticals Inc [NASDAQ:APLS]’s Current Ratio is 3.54. Further, the Quick Ratio stands at 3.10, while the Cash Ratio is 1.71. Considering the valuation of this stock, the price to sales ratio is 2.50, the price to book ratio is 6.34 and price to earnings (TTM) ratio is 67.70.
Transactions by insiders
Recent insider trading involved Watson David O., Officer, that happened on Nov 17 ’25 when 5000.0 shares were purchased. Chief Financial Officer, Sullivan Timothy Eugene completed a deal on Oct 21 ’25 to sell 10000.0 shares. Meanwhile, Officer Sullivan Timothy Eugene bought 10000.0 shares on Oct 21 ’25.
